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Glutamate is a critical neurotransmitter of the central nervous system (CNS) and also an important
regulator of cell survival and proliferation. The binding of glutamate to metabotropic glutamate receptors
induces signal transduction cascades that lead to gene-specific transcription. The transcription factor NF-B,
which regulates cell proliferation and survival, is activated by glutamate; however, the glutamate receptor-
induced signaling pathways that lead to this activation are not clearly defined. Here we investigate the
glutamate-induced activation of NF-B in glial cells of the CNS, including primary astrocytes. We show that
glutamate induces phosphorylation, nuclear accumulation, DNA binding, and transcriptional activation func-
tion of glial p65. The glutamate-induced activation of NF-B requires calcium-dependent IB kinase  (IKK)
and IKK activation and induces p65-IB dissociation in the absence of IB phosphorylation or degra-
dation. Moreover, glutamate-induced IKK preferentially targets the phosphorylation of p65 but not IB.
Finally, we show that the ability of glutamate to activate NF-B requires cross-coupled signaling with the
epidermal growth factor receptor. Our results provide insight into a glutamate-induced regulatory pathway
distinct from that described for cytokine-induced NF-B activation and have important implications with
regard to both normal glial cell physiology and pathogenesis.
Glutamate, the major excitatory neurotransmitter of the
central nervous system (CNS), regulates many physiological
functions in the nervous system, including cell proliferation,
differentiation, and survival (2, 16, 20). Glutamate activates
neuronal and glial cells through ionotropic and metabotropic
glutamate receptors (mGluRs) (13, 30). In neurons, glutamate
is an essential signaling component regulating synaptic plastic-
ity and other physiological processes (24). Glutamate-induced
Ca2 elevation is also believed to promote excitotoxic neuronal
cell death associated with brain injury and disease (15). Recently,
particular attention has been paid to the role of mGluRs in
regulating glial cell functions such as proliferation, glutamate up-
take, and modulation of neuronal activity (10, 35, 38).
mGluR5 is one of the most abundant and best-characterized
glutamate receptors in glial cells. The stimulation of mGluR5
has been shown to promote cytosolic Ca2 release, glutamate
transporter 1 (GLT-1)/excitatory amino acid transporter 2
(EAAT2)-mediated glutamate uptake (37), immediate-early
gene expression (6), and glial cell proliferation and survival
(10). Additionally, mGluR5 expression is rapidly upregulated
by treatment with growth factors and in response to injury (36).
The signaling cascade initiated by mGluR stimulation has been
recently investigated. In one study, it was shown that mGluR5
stimulation leads to the activation of extracellular signal-reg-
ulated kinase 1/2 and the epidermal growth factor receptor
(EGFR) in astrocytes (23). Similarly to mGluR5, EGFR sig-
naling promotes Ca2 oscillation in astrocytes (22), and the
EGFR is upregulated in astrocytes in response to injury (14).
Interestingly, it was recently demonstrated that in the hip-
pocampus, mGluR5 activates NF-B, an evolutionarily con-
served transcription factor that has critical roles in regulating
cell survival, proliferation, and immune/inflammatory re-
sponses (8).
The mammalian NF-B family consists of five members:
RelA (RelA/p65), RelB, c-Rel, NF-B1 (p105/p50), and NF-
B2 (p100/p52). These homo- and heterodimeric proteins
share a conserved N-terminal Rel homology domain harboring
motifs that mediate nuclear localization, DNA binding, and
interaction with inhibitory IB proteins in the cytoplasm. In
the classical pathway of NF-B activation, the signal-depen-
dent phosphorylation of IB on Ser32/Ser36 by the IKK com-
plex triggers IB polyubiquitination and degradation. NF-B
subsequently translocates to the nucleus and regulates the
transcription of target genes (1). The IKK complex is com-
prised of two catalytic subunits, IKK and IKK, as well as the
regulatory subunit, NEMO/IKK (11). In addition to IB,
IKK phosphorylates other proteins in the NF-B signaling
pathway, including p65 (28). However, IKK has not been dem-
onstrated to preferentially phosphorylate distinct substrates in
response to specific stimuli.
NF-B is widely expressed throughout the CNS where it is
involved in neuroinflammatory responses, as well as CNS-spe-
cific functions such as synaptic plasticity, long-term memory,
and neurodegeneration (19, 21). NF-B is activated by a wide
variety of CNS-specific stimuli, including neurotrophins and
neurotransmitters. In this regard, glutamate has been shown to
activate NF-B in neurons (9), and there are a few reports
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describing the glutamate-induced regulation of NF-B in pri-
mary astrocytes (4, 5). However, the signaling pathways that
regulate NF-B in specific cells of the CNS are not well de-
fined. We previously reported that NF-B can regulate the
expression of the glutamate transporter EAAT2/GLT-1 in glial
cells (33), and we hypothesized that NF-B-mediated regula-
tion of EAAT2 may be part of a regulatory feedback mecha-
nism in response to extracellular glutamate signaling.
In this study, we investigated the mechanisms whereby glu-
tamate activates NF-B activity in glial cells. We demonstrate
that in glial cells of the CNS, glutamate activates NF-B
through mGluR5 in an IKK/-dependent manner that in-
duces p65-IB dissociation but is not associated with IB
phosphorylation or degradation. Notably, our data demon-
strate that glutamate-induced IKK preferentially targets the
phosphorylation of p65 but not IB in vitro. Our results also
show that glutamate regulation of NF-B requires calcium and
cross-coupled signaling with the EGFR. These findings high-
light the diversity of signaling pathways that modulate NF-B
activity and underscore the importance of cross talk among
different classes of receptors to control gene expression.
MATERIALS AND METHODS
Cells and reagents. H4 cells were obtained from ATCC and grown in Dul-
becco’s modified Eagle’s medium plus 10% fetal bovine serum (FBS). U87-MG
cells were obtained from ATCC and grown in minimal essential medium plus
10% FBS, nonessential amino acids, and Na-pyruvate. Primary mouse astrocytes
were dissected from 3- to 5-day-old cortices and stained for immunoreactivity to
glial fibrillary acidic protein (data not shown). Brain pieces were digested in
0.05% trypsin-EDTA (Gibco-BRL) at 37°C for 30 min, followed by repeated
trituration to form single-cell suspensions. The cells were plated in Dulbecco’s
modified Eagle’s medium plus 10% FBS (Gibco-BRL). The cells were highly
enriched for glial fibrillary acidic protein immunostaining (data not shown).
L-Glutamic acid and (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) were pur-
chased from Tocris Neurochemicals. Cultures were switched to 0.5% serum for
14 to 24 h before treatments with glutamate, CHPG, EGF, or tumor necrosis
factor alpha (TNF-). BAPTA-AM and MG-132 were used at final concentra-
tions of 10 M and 1 M, respectively. Lapatinib and gefitinib were gifts from
H. S. Earp (UNC-Chapel Hill).
EMSAs and ChIP assays. Electromobility shift assays (EMSAs) were per-
formed as previously described (18). Briefly, 4 to 5 g of nuclear extracts were
prepared following cell stimulation and incubated with a radiolabeled DNA
probe containing an NF-B consensus site from the  light-chain enhancer
(Promega) or the EAAT2 promoter (33). For supershifts, 1 l of anti-p65
antibody (SC-109; Santa Cruz) or 2 l of anti-p50 antibody (SC-7178; Santa
Cruz) was added to the binding reaction. Protein-DNA complexes were resolved
on a nondenaturing polyacrylamide gel and visualized by autoradiography. Chro-
matin immunoprecipitation (ChIP) analysis was performed as previously de-
scribed (33) with some modifications. Briefly, protein-DNA complexes were
cross-linked with formaldehyde, and the cells were harvested and then either
snapfrozen in dry ice/ethanol and stored at 80°C or immediately used. DNA
from the cell lysates was sonicated to lengths of 500 to 1,000 bp, and 5 g of a
p65 antibody (SC-109; Santa Cruz) was used for immunoprecipitation overnight
at 4°C. Primers (5-ATGTCAGCTCTCGACGAAAATAGA-3 [forward] and
5-GGAGGGATTGCAAGGTTTAGC-3 [reverse]) to amplify the EAAT2
583 promoter region were designed using PrimerExpress (ABI).
Transient transfection reporter assay. Cells were seeded in 24-well plates at 1 	
104 cells/well and transfected with Fugene (Roche) according to the manufac-
turer’s protocol. A total of 500 ng of DNA was used for each well: 100 ng of
EAAT2-luciferase reporter and 50 ng of pRL-TK (renilla reporter control) DNA
were used for transfection. Medium containing 0.5% FBS and EGF (100 ng/ml),
TNF- (20 ng/ml), or glutamate (400 M) was added to the wells for the next 24
to 48 h. The cells were harvested after 24 to 48 h of treatment. Luciferase assays
were performed using a dual luciferase assay system (Promega), and activity was
measured using an Lmax luminometer (Molecular Devices). All transfections
were performed in triplicate.
Immunoprecipitation, Western blot analysis, and kinase assays. The following
antibodies were used for immunoprecipitation/Western blot analysis: phospho-
Ser536 (CST#3031; Cell Signaling Technologies), total p65 (SC-8008; Santa
Cruz), phospho-IKK/-Ser180/181 (CST#2681), total IKK (Upstate 05-536),
total IKK (Upstate 05-535), phospho-IB-Ser32/36 (CST#9246), total IB
(SC-371), phospho-AKT (CST#9271), and total AKT (CST#9272). To detect
phosphorylated EGFR, the total EGFR was immunoprecipitated with
CST#2232. Immunoprecipitated lysates were subject to Western blot analysis
with different phospho-EGFR antibodies: Y1173 (CST#4407) and Y845 (Up-
state 07-820). Secondary immunoglobulin G (IgG)-horseradish peroxidase anti-
bodies were obtained from Promega. For the Western blot analysis, 10 to 30 g
of protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) using 4 to 12% Bis-Tris gels (Invitrogen). Protein was
transferred onto polyvinylidene difluoride or nitrocellulose membranes, and
Western blot assays were performed according to the specific manufacturer
guidelines for each antibody. For IKK kinase assays, IKK was immunoprecipi-
tated from whole-cell lysates (Upstate 05-536) and incubated with recombinant
glutathione S-transferase (GST)–IB or GST-p65 fragments and [-32P]ATP.
The proteins were resolved by SDS-PAGE and analyzed by autoradiography.
Nonsaturating exposures of Western blots were scanned into Adobe Photoshop,
and the average pixel density was calculated using the NIH Scion software.
siRNA knockdown. All small interfering RNAs (siRNAs) were purchased from
Dharmacon. The cells were seeded in six-well plates at 1 	 105 cells/well. The
following siRNAs were purchased from Dharmacon, and transfections were
performed according to the manufacturer’s protocol using Dharmacon transfec-
tion reagent 1: IKK (M-003473-01), IKK (M-003503-00), EGFR (M-003114-
01), and mGluR5 (M-005620-02). For control transfections, we used Dharmacon
nontargeting siRNA control 2 (D-001210-02). The cells were serum starved for
14 to 16 h before treatments and harvesting. Western blot analysis was per-
formed as described above.
Calcium and proliferation assays. The cells were seeded in a 96-well plate at
1 	 103 cells/well. After overnight serum starvation, the cells were treated with
dimethyl sulfoxide (DMSO), lapatinib (1 M), gefitinib (1 M), or compound A
(1 M) for 48 h. The level of intracellular calcium was measured using a Fluo-4
NW calcium assay kit (F36205; Invitrogen) according to the manufacturer’s
directions. The level of relative fluorescence was measured using an Optima-
Fluor 96-well fluorometer. Cell metabolic activity was measured using an XTT/
MTT assay cell titer kit (Promega) according to the manufacturer’s protocol
using a Vmax microplate reader (Molecular Devices).
RESULTS
Glutamate regulates NF-B activity and phosphorylation in
glial cells. To investigate glutamate-induced responses in glial
cells, we first examined the ability of glutamate to regulate
NF-B DNA binding. We found that the glutamate treatment
of H4 glioma cells stimulated DNA binding to the  enhancer
light-chain NF-B element (Fig. 1a) as well as to an NF-B
binding site in the promoter of EAAT2/GLT-1, a gene we
previously demonstrated to be regulated in an NF-B-depen-
dent manner (33) (Fig. 1b). Supershift studies with specific
antibodies demonstrate that the glutamate-induced complexes
contain p65 and p50 subunits. Similar results were observed
with U87-MG cells (data not shown). Next, we used ChIP
assays to determine if glutamate induces the recruitment of
NF-B in vivo. The results from these experiments demon-
strated the recruitment of p65 to the EAAT2 promoter with
glutamate treatment for 10 and 30 min (Fig. 1b). Finally, we
determined whether glutamate could activate a luciferase re-
porter construct driven by the promoter of EAAT2/GLT-1
(33). In H4 cells transiently transfected with an EAAT2-lucif-
erase reporter containing wild-type NF-B consensus se-
quences, glutamate treatment significantly increased luciferase
activity to an extent similar to that seen with EGF. In contrast,
the ability of glutamate to activate an EAAT2-luciferase re-
porter containing mutated NF-B consensus sites was signifi-
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cantly diminished (Fig. 1c), demonstrating that the regulation
of EAAT2 by glutamate is NF-B dependent.
Upon stimulation with activating signals, many proteins in
the NF-B pathway, including IKK/, IB, and p65, un-
dergo inducible, site-specific phosphorylation (8, 11). Having
shown that glutamate can regulate NF-B DNA binding and
transcriptional activity, we next examined whether glutamate
induces the phosphorylation of proteins in the NF-B signaling
pathway. Using Western blot analysis of whole-cell lysates iso-
lated from H4 glial cells, glutamate was shown to induce the
rapid phosphorylation of p65 at Ser536 (Fig. 2a), which is a
marker of transcriptional activation. Additionally, glutamate
induced the phosphorylation of IKK/ at specific sites in the
activation loop (IKK-Ser180/IKK-Ser181) that are impor-
FIG. 1. Glutamate regulates NF-B DNA binding and transcriptional activity. (a) EMSAs were performed using nuclear extracts from
glutamate or TNF-treated H4 cells and radiolabeled oligonucleotides corresponding to an NF-B consensus site from the  light-chain enhancer
(Promega) or the human EAAT2 promoter. Supershift assays were performed with the indicated antibodies. Arrows indicate p65-containing
complexes. *, supershifted complexes. (b) ChIP assays were performed using IgG or p65 antibody in U87-MG cells that were untreated or treated
with glutamate at the indicated time points. PCR analysis was performed using primers spanning the 583 NF-B site of the EAAT2 promoter
(see Materials and Methods). (c) A wild-type (WT) or NF-B mutant (Mut) EAAT2-luciferase (luc) reporter was transfected into H4 cells and
treated with glutamate or EGF at the indicated doses for 14 to 16 h. Whole-cell lysates were prepared and monitored for luciferase activity. The
relative luciferase values represent units of luciferase normalized to renilla. The results from a representative experiment are shown. Error bars
represent standard deviations (n 
 3). Glu, glutamate.
FIG. 2. Glutamate and mGluR5 stimulation induce the phosphorylation of p65 and IKK. Western blot analysis was performed on whole-cell
lysates from H4 cells (a) and mouse primary astrocytes (b) treated with TNF-, EGF, glutamate, or CHPG for 10 min using the indicated
antibodies. Similar results were seen with U87-MG cells (data not shown). untr., untreated. (c) H4 cells were transfected with siRNA targeting
mGluR5 and subsequently treated with glutamate (Glu) for 15 min. Western blot analysis was performed on whole-cell lysates using the indicated
antibodies. unt., untreated.
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tant for kinase activation, suggesting an involvement of an
IKK-regulated pathway in the glutamate response (Fig. 2a).
The treatment of glial cells with EGF also led to the phosphor-
ylation of p65 and IKK/ (Fig. 2a). Similar results were ob-
served in primary murine astrocytes treated with glutamate
and EGF (Fig. 2b).
It has been previously reported that mGluR5 can regulate
EAAT2 expression in astrocytes (37). Therefore, we sought to
determine whether the glutamate-induced regulation of
NF-B involved mGluR5. We found that primary astrocytes
treated with the mGluR5-specific agonist CHPG showed in-
creased phosphorylation of p65 and IKK/ to a similar extent
as treatment with glutamate (Fig. 2b). Using the siRNA-me-
diated knockdown of gene expression, we directly tested the
role of mGluR5 in mediating glutamate induction of NF-B.
The results from these experiments revealed diminished glu-
tamate-induced phosphorylation of p65 in the presence of
siRNA targeting mGluR5 compared with a nontargeting con-
trol siRNA (Fig. 2c). These data demonstrate that the gluta-
mate-induced regulation of NF-B is mediated, at least partly,
by mGluR5.
Glutamate activates NF-B in the absence of IB phosphor-
ylation/degradation. We next sought to determine whether the
glutamate-induced activation of NF-B involved IB, whose
proteolytic regulation is an inherent component of the classical
NF-B signaling pathway (3, 28). Notably, we found that treat-
ment with glutamate failed to induce the phosphorylation of
IB at Ser32/Ser36 (Fig. 3a), which is typically required for
subsequent IB proteolytic processing and NF-B activation.
Similarly, EGF treatment did not induce IB phosphoryla-
tion (Fig. 3a). Consistent with the lack of glutamate-induced
IB-Ser32/Ser36 phosphorylation, IB protein levels re-
mained stable in the presence of glutamate, whereas TNF-
induced both IB-Ser32/Ser36 phosphorylation and degrada-
tion (Fig. 3a). We confirmed that glutamate activates NF-B in
a manner that is independent of IB degradation by exam-
ining the ability of glutamate to regulate NF-B DNA binding
and p65 phosphorylation in the presence of proteosome inhi-
bition. As expected, the proteosome inhibitor MG-132 abro-
gated the TNF-induced degradation of IB, resulting in the
stabilization of total IB (Fig. 3b) and demonstrating the
efficacy of proteosome inhibition. Furthermore, we observed
that the pretreatment of U87-MG cells with MG-132 stabilized
levels of basal phosphorylated and total IB. Moreover, our
data revealed that glutamate-induced NF-B DNA binding
was only slightly affected in the presence of MG-132, whereas
TNF-induced DNA binding was significantly diminished. Ad-
ditionally, we observed diminished TNF-induced p65 phosphor-
ylation in the presence of MG-132. However, EGF- and glu-
tamate-induced p65 phosphorylation persisted under these
conditions (Fig. 3b). These results demonstrate that the deg-
radation of IB is not required for the regulation of NF-B
DNA binding and p65 phosphorylation induced by EGF and
glutamate.
To address how glutamate activates NF-B in the absence of
IB degradation, we characterized the effect of glutamate on
FIG. 3. Glutamate/mGluR5 attenuates p65-IB interaction in the absence of IB phosphorylation/degradation. (a) Whole-cell lysates were
isolated from H4 cells treated with TNF- (10 ng/ml), EGF (100 ng/ml), or glutamate (400 M) for 30 min. Western blot analysis was performed
on 10 to 30 g protein using antibodies to phospho-IB and total IB. (b) Untreated U87-MG cells or cells treated with 1 M of MG-132 were
stimulated with glutamate (400 M), EGF (100 ng/ml), or TNF- (20 ng/ml) for 15 min, and whole-cell lysates were harvested for Western blot
analysis to examine phospho-IB-Ser32/36 and total IB to verify the efficacy of proteosome inhibition. Western blot analysis was also
performed using antibodies to phospho-p65-Ser536 and total p65. Similarly treated cells were used to isolate nuclear fractions for EMSA using the
 light-chain enhancer NF-B probe. (c) Antibodies to IgG or p65 (5 g each) were used to immunoprecipitate endogenous proteins from 250
g of U87-MG whole-cell lysates that were untreated (U) or treated with TNF- (T; 20 ng/ml) or glutamate (G; 400 M) for 30 min. Western
blot analysis was performed on immunoprecipitates using antibodies to IB, p50 (SC-7178; Santa Cruz) or p65 (SC-109; Santa Cruz). The pixel
densities of IB and p65 Western blots were quantitated using NIH Scion software. Graphs represent the pixel density for IB normalized to
p65 for each experimental condition. Unt, untreated; Glu, glutamate; IP, immunoprecipitate.
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the interaction between p65 and IB. Examining the interac-
tions between endogenous proteins using coimmunoprecipita-
tion experiments from whole-cell H4 glioma lysates revealed
that the interaction between p65 and IB was reduced by
approximately 50% in glutamate-treated cells compared to
untreated cells. As expected, and as a control, glutamate did
not significantly affect the interaction between p65 and p50
(Fig. 3c). In additional control experiments, TNF- treatment
significantly attenuated the interaction between p65 and IB
but not between p65 and p50 (Fig. 3c). Similar results were
seen with the U87-MG glioblastoma cells (data not shown).
These data indicate that glutamate-induced signaling leads to
reduced interaction between p65 and IB.
Glutamate induces p65 nuclear accumulation and enhanced
transactivation potential. Based on the finding that glutamate
induces the dissociation of p65-IB complexes, we next ex-
amined whether glutamate induces the accumulation of nu-
clear p65. The levels of p65 were examined in cytoplasmic and
nuclear subcellular fractions of U87-MG cells treated with
glutamate, EGF, or CHPG. The results from these experi-
ments demonstrate that both glutamate and EGF induce the
nuclear accumulation of p65 at 10 and 60 min (Fig. 4a). The
TNF-induced nuclear accumulation of p65 at 10 min is shown
as a positive control, and the purity of nuclear and cytoplasmic
fractions was verified by examining the subcellular localization
of -tubulin and lamin A/C (Fig. 4a and b). Additionally, we
observed that CHPG induced the accumulation of phosphory-
lated p65-Ser536 in nuclear fractions starting at 5 min and
persisting over the course of 1 h (Fig. 4b). Nuclear levels of
phosphorylated p65-Ser536 accumulation coincided with its
loss in cytoplasmic fractions from 10 to 60 min. We also ob-
served an increase in total nuclear p65 with CHPG treatment
FIG. 4. Glutamate induces p65 nuclear accumulation and transactivation. Nuclear and cytoplasmic fractions were isolated from U87-MG cells
treated with glutamate (Glu; 400 M), EGF (100 ng/ml), or TNF- (20 ng/ml) (a) or CHPG (200 M) (b) at the indicated time points. Western
blot analysis was performed using the indicated antibodies. -Tubulin and lamin A/C were used as controls for loading and subcellular
fractionation. Unt., untreated. (c) Glutamate increases p65 transcriptional activation. H4 cells were transiently transfected with a Gal4-luciferase
reporter (Gal4-luc) and either Gal4-Elk1(TAD) or Gal4-p65(TAD) fusion proteins. Cells were serum starved overnight and stimulated with
glutamate (Glu; 400 M), EGF (100 ng/ml), or TNF- (20 ng/ml) for 14 to 16 h and monitored for luciferase and renilla activity. Relative luciferase
values represent units of luciferase normalized to renilla. Error bars represent standard deviations (n 
 3). unt, untreated.
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at 10 and 30 min, which diminished at 60 min (Fig. 4b). Similar
results were observed with H4 cells (data not shown). Overall,
these data indicate that glutamate and mGluR5 stimulation
results in the nuclear accumulation of p65.
Based on the result that glutamate induces the phosphory-
lation of p65 at Ser536, we next used a Gal4-luciferase-based
reporter assay to determine whether glutamate could therefore
regulate p65 transcriptional activity. In this assay, a fusion
protein containing the Gal4 DNA binding domain linked to
the p65 transcriptional activation domain (TAD) is cotrans-
fected with a luciferase reporter under the control of Gal4
regulatory sites (Gal4-luciferase). Since DNA binding is medi-
ated by the Gal4 regulatory elements, this assay specifically
monitors the ability of the p65 TAD to induce Gal4-luciferase
activity. In transiently transfected glial cells, both Gal4-p65 and
a control fusion protein, Gal4-Elk1, very modestly increased
the activity of the Gal4-luciferase reporter. Importantly, while
treatment with glutamate had little effect on Gal4-Elk1, it
significantly potentiated the activity of Gal4-p65 (Fig. 4c). In
further experiments, it was found that EGF and TNF- treat-
ment increased the activity of Gal4-p65 but not Gal4-Elk1
(Fig. 4c). These results demonstrate that, in addition to induc-
ing the nuclear accumulation of p65, the glutamate treatment
of glial cells regulates p65 through its TAD.
IKK is required for the glutamate/CHPG induction of RelA/
p65 phosphorylation. Interestingly, our results have revealed
that glutamate treatment increases IKK/ and p65 phosphor-
ylation, although this does not correlate with the increased
phosphorylation/degradation of IB. Therefore, we examined
the ability of glutamate receptor-induced IKK to target the
phosphorylation of both p65 and IB in vitro. IKK complexes
were immunoprecipitated from untreated U87-MG cells, or
cells treated with glutamate or TNF- and used to perform in
vitro kinase assays with a purified GST-p65314 to 551 corre-
sponding to the transactivation domain of p65, or GST-
IB1 to 50 recombinant proteins as substrates. We found that
while TNF- was able to potently stimulate the IKK-mediated
phosphorylation of both p65 and IB, the mGluR5 agonist
CHPG preferentially stimulated the phosphorylation of p65
(Fig. 5a). These results suggest that glutamate receptor stim-
ulation signals NF-B in a manner that is distinct from the
classical activation pathway and demonstrate the ability for
distinct signals to differentially specify IKK targets.
Next, the role of IKK in the glutamate-induced activation of
NF-B was confirmed using pharmacological inhibition and
siRNA knockdown strategies. In H4 cells pretreated with com-
pound A, a well-established specific inhibitor of IKK (39), we
observed not only the loss of basal NF-B phosphorylation but
also the greatly diminished induction of p65-Ser536 phosphor-
ylation by glutamate, CHPG, or TNF- (Fig. 5b). Next, to
determine whether IKK is required for the glutamate-induced
regulation of NF-B, the expression of IKK and IKK was
inhibited by siRNA. In these experiments, the 90% knock-
down of both IKK and IKK subunits was obtained with
specific siRNA transfection (Fig. 5c and d). Notably, the loss of
IKK suppressed glutamate receptor- and TNF--induced p65
phosphorylation (Fig. 5c), while the loss of IKK strongly
suppressed both basal and glutamate-induced p65-Ser536 phos-
phorylation (Fig. 5d). The loss of IKK significantly reduced
but did not completely suppress TNF--induced p65-Ser536
phosphorylation. These results demonstrate that the IKK com-
plex, utilizing both IKK and IKK, is a primary mediator of
glutamate-induced NF-B and suggest that IKK/ regulates
the p65 transactivation function and is not associated with the
induction of IB phosphorylation and degradation.
The EGFR signaling pathway is required for the glutamate-
mediated regulation of NF-B activity. Thus far, we have ob-
served the similar activation of NF-B in glial cells in response
to treatment with either EGF or glutamate. Interestingly, sim-
ilarly to mGluR5, EGFR signaling promotes calcium oscilla-
tion and its expression is increased in astrocytes in response to
injury (14, 22). Moreover, previous studies have shown that
FIG. 5. IKK is required for glutamate/CHPG induction of p65 phosphorylation. (a) IKK was immunoprecipitated from untreated (Untr.) and
TNF- or CHPG-treated U87-MG cells and incubated with GST-IB or GST-p65 and [-32P]ATP. Proteins were resolved by SDS-PAGE and
visualized by autoradiography. (b) U87-MG cells were pretreated with DMSO or compound A (Cmpd A) for 1 h, and cells were subsequently
treated with glutamate (Glu; 400 M), CHPG (200 M), or TNF- (10 ng/ml) for 10 min. Whole-cell lysates were isolated, and Western blot
analysis was performed using the indicated antibodies. untr., untreated. (c) H4 cells were transfected with siRNA targeting IKK. Twenty-four
hours after transfection, the cells were serum starved for 14 to 16 h and subsequently treated with CHPG or TNF- for 10 min. Whole-cell lysates
were isolated, and Western blot analysis was performed with the indicated antibodies. (d) H4 cells were transfected with siRNA targeting IKK
and analyzed as described for panel b.
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mGluR5 stimulation activates EGFR in astrocytes (23), sug-
gesting that there is cross talk between these two signaling
pathways. Therefore, we examined the role of EGFR in glu-
tamate signaling to NF-B using the pharmacological inhibi-
tion of EGFR or the siRNA-mediated knockdown of EGFR
expression. We found that the pretreatment of glial cells with
the EGFR-specific inhibitor gefitinib abrogated CHPG- but
not TNF--induced p65 phosphorylation (Fig. 6a). Further-
more, the loss of EGFR expression by siRNA knockdown
completely abolishes the ability of CHPG, but not TNF-, to
induce p65 phosphorylation (Fig. 6b). Taken together, our
results establish a requirement for EGFR in mGluR5 signaling
to NF-B, which is distinct from TNF- signaling.
To further characterize the potential cross-coupling between
mGluR5 and EGFR, we examined whether glutamate-induced
signals lead to EGFR phosphorylation, an indicator of EGFR
activation. Total EGFR was immunoprecipitated from cells
treated with either EGF or glutamate, and phosphospecific
antibodies were used to examine the phosphorylation status of
EGFR. The results from these experiments demonstrated that
glutamate induces the phosphorylation of EGFR at Tyr1173
and Tyr845 to a similar extent as that seen with EGF treatment
(Fig. 6c). Based on these results, we asked whether EGFR and
mGluR5 could form a complex in cells. In unstimulated cells,
a weak interaction was observed between EGFR and mGluR5,
and this interaction was robustly enhanced by glutamate treat-
ment (Fig. 6d). Importantly, EGF failed to potentiate interac-
tion between EGFR and mGluR5, demonstrating that the in-
creased interaction is specific for glutamate signaling. We
failed to observe an association between EGFR and mGluR3
(data not shown). These data suggest that functional cross talk
between EGFR and mGluR5 is important for the regulation of
NF-B activity in glial cells.
Inhibition of the EGFR attenuates glial cell proliferation
and mGluR5-mediated calcium mobilization. Interestingly,
glutamate and EGFR have been shown to induce calcium
release within cells (12, 22). To determine whether calcium-
regulated signaling is required for glutamate-induced NF-B
activity in glial cells, we examined the effects of the cell-per-
meable calcium chelator BAPTA-AM on glutamate-induced
NF-B phosphorylation. BAPTA-AM treatment significantly
attenuated CHPG-induced p65-Ser536 phosphorylation (Fig.
7a), as well as glutamate-induced IKK/ phosphorylation
(Fig. 7b). As an additional control, H4 cells were treated with
N,N,N,N-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN),
a high-affinity, heavy metal chelator that has low affinity for
calcium. While TPEN increased basal p65-Ser536 phosphory-
lation, it did not prevent the additional phosphorylation of p65
with either CHPG or TNF- treatment (Fig. 7a). These results
demonstrate that the effects of glutamate on NF-B activation
are mediated by calcium.
EGFR activation has also been shown to promote calcium
oscillations (22) and the transactivation of mGluRs (23). To
address whether EGFR signaling to IKK/ and NF-B is
required for glutamate-induced calcium mobilization, glial
cells were treated with CHPG at the indicated concentrations
and calcium mobilization was monitored using a fluorescent
calcium indicator. We found that CHPG treatment greatly
enhanced the calcium response, which was significantly
blunted by treatment with the EGFR/ErbB2 inhibitor lapatinib
(Fig. 8a). Similar results were seen with gefitinib (data not
shown). These results demonstrate that glutamate receptor-
induced Ca2 release is dependent on EGFR-dependent sig-
naling. Finally, there is strong evidence that altered calcium
homeostasis is an important factor in neuronal death following
injury (15), and glutamate has been shown to regulate glial cell
proliferation and survival (2, 10, 27). To determine whether the
calcium mobilization induced by glutamate signaling through
mGluR5 and EGFR affects U87-MG cell proliferation, we
examined cellular metabolic activity, which is directly propor-
tional to the number of living cells in culture. We found that
glutamate, CHPG, and EGF treatment increased glial cell
FIG. 6. The EGFR signaling pathway is required for the glutamate regulation of NF-B activity. (a) H4 cells were pretreated with DMSO or
gefitinib for 1 h and subsequently treated with CHPG (200 M) or TNF- (10 ng/ml) for 10 min. Western blot analysis was performed on whole-cell
lysates using the indicated antibodies. unt., untreated. (b) H4 cells were transfected with siRNA targeting the EGFR. Twenty-four hours after
transfection, the cells were serum starved for 14 to 16 h and subsequently treated with CHPG or TNF- for 10 min. Whole-cell lysates were
isolated, and Western blot analysis was performed with the indicated antibodies. (c and d) EGFR or IgG was immunoprecipitated from whole-cell
lysates prepared from untreated or EGF- or glutamate-treated H4 cells. Cells were treated for 10 min. Western blot analysis was performed with
the indicated antibodies. IP, immunoprecipitate.
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viability/proliferation over 24 to 48 h (Fig. 8b). Importantly,
the cotreatment of cells with lapatinib or gefitinib decreased
both EGF- and glutamate-induced cell viability/proliferation
(Fig. 8b). Similarly, the inhibition of IKK activity using com-
pound A blocked both glutamate- and CHPG-induced cell
proliferation. Together these data establish that EGFR and
IKK signaling are required for the mGluR5 induction of cell
proliferation/survival.
DISCUSSION
NF-B plays essential roles in the CNS, controlling synaptic
plasticity, cell survival/death, and neurodegeneration (17).
Therefore, dissecting the regulation of NF-B is important
toward understanding signaling dynamics and disease mecha-
nisms in the CNS. Glutamate is an important signaling mole-
cule that has effects on both neurons and astrocytes and can
promote cell death and proliferation (2, 10). Here we have
studied the signaling pathways controlled by glutamate that
lead to NF-B activation. We have shown that the stimulation
of glial cells with glutamate leads to mGluR5 engagement of
EGFR resulting in calcium release and, ultimately, the IKK-
dependent activation of p65 to promote cell proliferation/sur-
vival (Fig. 8c). The results demonstrate that glutamate, like
TNF-, leads to the activation of IKK/. However, glutamate
does not lead to the phosphorylation and degradation of IB,
which is associated with classical signaling to NF-B. Indeed,
experiments using the proteosome inhibitor MG-132 demon-
strate that the degradation of IB is not required for the
glutamate-induced activation of NF-B DNA binding, as well
as p65 phosphorylation. Moreover, we find that glutamate sig-
nals to IKK in a calcium-dependent manner, leading to the
preferential phosphorylation of p65, not IB. These data
clearly show that distinct signals can differentially specify the
phosphorylation of IKK substrates and shed new light on our
fundamental understanding of the diverse signaling pathways
that regulate NF-B activation in different cell types.
mGluR5 belongs to the G protein-coupled receptor (GPCR)
family, several members of which have been shown to activate
NF-B (32). Recently, GPCR stimulation has been shown to
regulate NF-B activity in a manner that requires CARD and
MAGUK domain-containing protein 3 (CARMA3) (7). Inter-
estingly, Grabiner et al. reported that the loss of CARMA3
does not affect GPCR-induced IKK/ phosphorylation but is
associated with the loss of the GPCR-induced phosphorylation
of both p65 and IB. Their findings suggest that the induction
of IKK phosphorylation is not necessarily sufficient to induce
its kinase activity. However, the uncoupling of IKK phosphor-
ylation and its kinase activity observed in CARMA3 null cells
affected both IB and p65 phosphorylation, whereas our find-
ings describe the glutamate receptor-induced IKK phosphor-
ylation that specifically targets the phosphorylation of p65 but
not IB. We postulate that signal-dependent IKK substrate
specificity may be achieved by the formation of distinct IKK
complexes, possibly involving the signal-specific posttransla-
tional modification of IKK and/or its substrates to alter kinase-
substrate affinity. In this regard, the exact molecular mecha-
nisms leading from different stimuli to the activation of the
IKK complex are not clear but, in light of our findings, suggest
that there are likely different modes of activating IKK.
Interestingly, the data demonstrate that, similarly to gluta-
mate, EGF induces NF-B activation without concomitant
IB phosphorylation/degradation. It has been reported that
EGF induces tyrosine phosphorylation of IB, thereby caus-
ing its degradation through a ubiquitination-independent
pathway (31). However, in preliminary experiments, we were
unable to detect the tyrosine phosphorylation of IB in the
glutamate-induced NF-B activation pathway (data not
shown). It has also been reported that p65 phosphorylated on
Ser536 does not interact with and is not regulated by IB
FIG. 7. Intracellular calcium is required for CHPG-mediated p65 phosphorylation. (a) U87-MG cells were pretreated with DMSO,
BAPTA-AM (10 M), or TPEN (10 M) for 1 h and subsequently treated with glutamate (Glu; 400 M) or EGF (100 ng/ml) for 10 min.
Whole-cell lysates were prepared for Western blot analysis with the indicated antibodies. unt., untreated. (b) H4 cells were pretreated with DMSO
or BAPTA-AM (10 M) for 1 h and subsequently treated with glutamate (Glu; 400 M) or TNF- (10 ng/ml) for 10 min. Whole-cell lysates were
prepared for Western blot analysis with the indicated antibodies to examine phosphorylated and total IKK/. The pixel densities of the
phospho-IKK/ bands were determined using NIH Scion software and normalized to untreated DMSO (lane 1) or untreated BAPTA-AM (lane
5) to examine n-fold induction.
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(29), suggesting that the glutamate-induced phosphorylation of
p65-Ser536 may cause dissociation from IB and subsequent
p65-P536 nuclear accumulation. Alternatively, glutamate may
regulate another protein that disrupts the p65 or IB com-
plex, thereby releasing p65 to regulate gene expression. In this
regard, the phosphorylation of p65 at Thr254 has been re-
ported to mediate the association with Pin1, causing the dis-
sociation of p65 from IB (26). However, in the preliminary
data, we have not observed the glutamate-induced phosphor-
ylation of p65-Thr254. We are currently investigating the
mechanism(s) by which glutamate induces p65-IB dissocia-
tion.
Finally, our studies demonstrate that mGluR5 signaling to
NF-B in glial cells requires cooperation with the EGFR. Pre-
viously, it was reported that glutamate induces an association
between the EGFR and mGluR5 (23). Our data (Fig. 6) indi-
cate that the interaction between the EGFR and mGluR5
increases following the treatment of glial cells with glutamate
but not in response to EGF. Importantly, pharmacological
inhibition studies indicate that a critical role for the EGFR in
this response is to control calcium release and NF-B activa-
tion. Our studies indicate that in response to mGluR5 signaling
in glial cells, EGFR-induced calcium release activates NF-B
through IKK/ to promote cell survival and proliferation.
Our data also suggest that cross talk between EGFR and
mGluR5 may be significant in glioblastoma, where increased
EGFR expression as well as constitutive NF-B activation has
been observed (25). It is possible that aberrant NF-B activity
observed in glioblastoma cells, which use glutamate as a cell
survival factor (34), is due to altered signaling by mGluR5 and
EGFR. Notably, the interaction between EGFR and mGluR5
is enhanced specifically with glutamate, but not EGF, treat-
ment. These findings are significant because they demonstrate
that glioblastoma cells may use alternative mechanisms to ac-
tivate EGFR to drive oncogenesis and, hence, account for the
lack of efficacy of current therapeutic strategies that target
EGFR activation.
Overall, these findings have important implications for new
therapeutic strategies for glioblastoma, which currently has
limited, dismal treatment options. The data presented here
FIG. 8. EGFR inhibition blocks cell proliferation and calcium signaling. (a) H4 cells were pretreated with DMSO or lapatinib (1 M) for 1 h
and subsequently treated with CHPG at the indicated doses for 10 min. Calcium mobilization was assayed using the Fluo4NW kit (Invitrogen).
Error bars indicate the standard deviations (n 
 3). (b) H4 cells were pretreated with DMSO, lapatinib, gefitinib, or compound A (Cmpd A) (1
M each) for 1 h and subsequently treated with glutamate (Glu; 400 M), CHPG (200 M), or EGF (100 ng/ml) for 24 h. Cell metabolic activity
was measured using a colorimetric assay (Promega). Error bars indicate the standard deviations (n 
 4). (c) Model for glutamate signaling to
NF-B. Glutamate binding to mGluR5 triggers association with and transactivation of the EGFR leading to calcium mobilization, calcium-
dependent IKK/ phosphorylation, and dissociation of the p65-IB complexes. Glutamate also leads to p65 phosphorylation and enhanced p65
transcriptional activation. Circled P, Phosphorylation sites.
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clearly demonstrate that the glutamate regulation of NF-B is
distinct from that of the canonical NF-B activation pathway,
highlighting the diversity and complexity of signaling to NF-B
by different stimuli. Our findings also underscore the emerging
relevance of cross talk among different classes of receptors as
a means of combinatorial receptor signaling to control gene
expression.
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